3Barrons RW. Treatment strategies for recurrent oral aphthous ulcers, Am J Health Syst Pharm, 2001,58(1) :41-50, quiz 51-53.
4Grinspan D. Significant response of oral aphtosis to thalidomide treatment,J Am Acad Dermatol, 1985,12(1 Pt 1):85.
5Grinspan D, Blanco GF, Aguero S. Treatment of aphthae with thalidomide. J Am Acad Dermatol, 1989,20(6) : 1060-1063.
6Torras H, Lecha M, Mascaro JM. Thalidomide in the treatment of aphthosis and Behcet' s disease. 4 years' experience. Med Cutan Ibero Lat Am,1982, 10(2) : 103-112.
7Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol, 1990,126(7) :923-927.
8Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet' s syndrome. A randomeized , double-blind, placebo-controlled trial. Ann Intern Med, 1998, 128(6):443-450.
9Wazieres B, Gil H, Magy N, et al. Treatment of recurrent ulceration with low doses of thalidomide. Piot study in 17 patients. Rev Med Interne,1999,20 ( 7 ) : 567 -570.
10JaeoKson JM, Greenspan JS, Sritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med, 1997,336(21) : 1487-1493.
4Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: Report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis [J ]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2005, 100(1) :40-51.
5Mignogna MS, Fedele S, Lo Russo L, et al. Field cancer- ization in oral lichen planus [ J ]. Eur J Surg Oncol, 2007, 33(3) :383 -389.
6Sugerman PB, Savage NW, Walsh I3, et at. The pathogen- esis of oral lichen planus [ J]. Crit Rev Oral Biol Med, 2002, 13(4): 350-365.
7Sklavnunou A, Ndrilopoulou A, Chrysomali E, et al. Elve- ated serum levels of the apoptosis related molecules TNF-c~. Fas/Apo-1 and Bcl-2 in oral lichen planus[J]. J OralPathol Med, 2008, 33 (7) : 386.
8Rhodus NL, Cheng B, Myers S, et al. A comparison of the proinflammatory, NF-kappaB-depe-ndent cytokines: TNF- edpha, IL-l-alpha, IL-6, and IL-8 in different oral fluids from oral lichen lanus patients [ J]. Clin Immunol, 2005, 114(3) :278 -283.
9Zidi I, Mestiri S, Bartegi A, et al. TNF-cdpha and its in- hibitors in cancer [ J ]. Med Oncol, 2010,27 ( 2 ) : 185 - 198.
10Dereure O, Basset-Seguin N, Guilhou JJ, et al. Erosive li- chen planus: Dramatic response to thalidomide [ J ].Arch Dermatol, 1996,132( 11 ) : 1392 - 1393.
